Merck & Co., Inc. (MRK): Cost of Revenue
$16.38B
Year ended 2025-12-31
$18.00B
Trailing 12 months to 2026-06-30
-2.0%
3-year compound annual growth
+3.8%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.38B | +7.8% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $15.19B | -5.8% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $16.13B | -7.4% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $17.41B | +27.8% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $13.63B | +0.1% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $13.62B | +13.3% | 2023-02-24, From 2020-01-01 |
| 2019-12-31 | $12.02B | n/c | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $13.51B | +4.6% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $12.91B | -8.0% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $14.03B | n/a | 2019-02-27, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | 2025-12-31 | $16.38B | +7.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $11.05B | +31.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $16.07B | -10.0% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $18.20B | +7.7% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $13.94B | -0.2% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $30.26B | +10.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $19.32B | +3.3% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $8.32B | -1.9% |
| Viatris Inc (VTRS) | 2025-12-31 | $9.29B | +1.9% |
Compare MRK, LLY, PFE, ABBV side by side · Screen every company in Pharmaceutical Preparations ↗